Noncanonical CALR variants
Am J Clin Pathol. 2023 Dec 20:aqad170. doi: 10.1093/ajcp/aqad170. Online ahead of print.NO ABSTRACTPMID:38124547 | DOI:10.1093/ajcp/aqad170 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 21, 2023 Category: Pathology Authors: Stephen E Langabeer Source Type: research

Reply to "Noncanonical CALR variants"
Am J Clin Pathol. 2023 Dec 20:aqad171. doi: 10.1093/ajcp/aqad171. Online ahead of print.NO ABSTRACTPMID:38124540 | DOI:10.1093/ajcp/aqad171 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 21, 2023 Category: Pathology Authors: Kritika Krishnamurthy Source Type: research

Noncanonical CALR variants
Am J Clin Pathol. 2023 Dec 20:aqad170. doi: 10.1093/ajcp/aqad170. Online ahead of print.NO ABSTRACTPMID:38124547 | DOI:10.1093/ajcp/aqad170 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 21, 2023 Category: Pathology Authors: Stephen E Langabeer Source Type: research

The trade-off between bias and imprecision: Debunking the myth of bias as the primary culprit in patient result misclassification
Am J Clin Pathol. 2023 Dec 19:aqad172. doi: 10.1093/ajcp/aqad172. Online ahead of print.NO ABSTRACTPMID:38113369 | DOI:10.1093/ajcp/aqad172 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 19, 2023 Category: Pathology Authors: Hikmet Can Çubukçu Source Type: research

Detection and quantification of Babesia species intraerythrocytic parasites by flow cytometry
CONCLUSIONS: This investigation demonstrates that Babesia parasites can be detected and quantified directly from venous blood using FLC. Although promising, opportunities remain to improve the general applicability of the method.PMID:38113371 | DOI:10.1093/ajcp/aqad168 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 19, 2023 Category: Pathology Authors: Patrick M Vanderboom Anisha Misra Kyle G Rodino Allison R Eberly Jason D Greenwood Heather E Morris Felicity C Norrie Emily C Fernholz Bobbi S Pritt Andrew P Norgan Source Type: research

Reply to "The trade-off between bias and imprecision: debunking the myth of bias as the primary culprit in patient result misclassification"
Am J Clin Pathol. 2023 Dec 19:aqad165. doi: 10.1093/ajcp/aqad165. Online ahead of print.NO ABSTRACTPMID:38113374 | DOI:10.1093/ajcp/aqad165 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 19, 2023 Category: Pathology Authors: Tze Ping Loh Chun Yee Lim Corey Markus Source Type: research

The trade-off between bias and imprecision: Debunking the myth of bias as the primary culprit in patient result misclassification
Am J Clin Pathol. 2023 Dec 19:aqad172. doi: 10.1093/ajcp/aqad172. Online ahead of print.NO ABSTRACTPMID:38113369 | DOI:10.1093/ajcp/aqad172 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 19, 2023 Category: Pathology Authors: Hikmet Can Çubukçu Source Type: research

Detection and quantification of Babesia species intraerythrocytic parasites by flow cytometry
CONCLUSIONS: This investigation demonstrates that Babesia parasites can be detected and quantified directly from venous blood using FLC. Although promising, opportunities remain to improve the general applicability of the method.PMID:38113371 | DOI:10.1093/ajcp/aqad168 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 19, 2023 Category: Pathology Authors: Patrick M Vanderboom Anisha Misra Kyle G Rodino Allison R Eberly Jason D Greenwood Heather E Morris Felicity C Norrie Emily C Fernholz Bobbi S Pritt Andrew P Norgan Source Type: research

Reply to "The trade-off between bias and imprecision: debunking the myth of bias as the primary culprit in patient result misclassification"
Am J Clin Pathol. 2023 Dec 19:aqad165. doi: 10.1093/ajcp/aqad165. Online ahead of print.NO ABSTRACTPMID:38113374 | DOI:10.1093/ajcp/aqad165 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 19, 2023 Category: Pathology Authors: Tze Ping Loh Chun Yee Lim Corey Markus Source Type: research

HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer
CONCLUSIONS: Copy number data from our NGS panel strongly correlate with HER2 status. Using a stringent cutoff, ERBB2 log2 ratio accurately predicts HER2 positivity with high specificity. The NGS CN assessment may have utility in determining HER2 status in certain clinical settings.PMID:38104247 | DOI:10.1093/ajcp/aqad167 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 17, 2023 Category: Pathology Authors: Daniel Xia Frank Kuo Melissa Hughes Neal Lindeman Danielle Manning Janet Files Sarah Strauss Greg Kirkner Ayesha Mohammed-Abreu Eric Winer Sara M Tolaney Nancy U Lin Deborah A Dillon Source Type: research

Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing
CONCLUSIONS: Afirma XA improved risk stratification of thyroid disease with a high risk of malignancy in Afirma GSC suspicious nodules. A negative Afirma XA result, however, should not be used as a rule-out test.PMID:38104250 | DOI:10.1093/ajcp/aqad169 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 17, 2023 Category: Pathology Authors: Carlos A Munoz-Zuluaga Jonas J Heymann James P Solomon Ami Patel Momin T Siddiqui Theresa Scognamiglio Hamza N Gokozan Source Type: research

HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer
CONCLUSIONS: Copy number data from our NGS panel strongly correlate with HER2 status. Using a stringent cutoff, ERBB2 log2 ratio accurately predicts HER2 positivity with high specificity. The NGS CN assessment may have utility in determining HER2 status in certain clinical settings.PMID:38104247 | DOI:10.1093/ajcp/aqad167 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 17, 2023 Category: Pathology Authors: Daniel Xia Frank Kuo Melissa Hughes Neal Lindeman Danielle Manning Janet Files Sarah Strauss Greg Kirkner Ayesha Mohammed-Abreu Eric Winer Sara M Tolaney Nancy U Lin Deborah A Dillon Source Type: research

Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing
CONCLUSIONS: Afirma XA improved risk stratification of thyroid disease with a high risk of malignancy in Afirma GSC suspicious nodules. A negative Afirma XA result, however, should not be used as a rule-out test.PMID:38104250 | DOI:10.1093/ajcp/aqad169 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 17, 2023 Category: Pathology Authors: Carlos A Munoz-Zuluaga Jonas J Heymann James P Solomon Ami Patel Momin T Siddiqui Theresa Scognamiglio Hamza N Gokozan Source Type: research

HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer
CONCLUSIONS: Copy number data from our NGS panel strongly correlate with HER2 status. Using a stringent cutoff, ERBB2 log2 ratio accurately predicts HER2 positivity with high specificity. The NGS CN assessment may have utility in determining HER2 status in certain clinical settings.PMID:38104247 | DOI:10.1093/ajcp/aqad167 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 17, 2023 Category: Pathology Authors: Daniel Xia Frank Kuo Melissa Hughes Neal Lindeman Danielle Manning Janet Files Sarah Strauss Greg Kirkner Ayesha Mohammed-Abreu Eric Winer Sara M Tolaney Nancy U Lin Deborah A Dillon Source Type: research

Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing
CONCLUSIONS: Afirma XA improved risk stratification of thyroid disease with a high risk of malignancy in Afirma GSC suspicious nodules. A negative Afirma XA result, however, should not be used as a rule-out test.PMID:38104250 | DOI:10.1093/ajcp/aqad169 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - December 17, 2023 Category: Pathology Authors: Carlos A Munoz-Zuluaga Jonas J Heymann James P Solomon Ami Patel Momin T Siddiqui Theresa Scognamiglio Hamza N Gokozan Source Type: research